

**Clinical Trials Summary for out of hours
Important Reference**

Acronym study title	TRIDENT – Tumour Treating Field (TTF) concomitant with radiation therapy and temozolomide for newly diagnosed glioblastoma
Study Details	Patients are randomized to have TTF either with both chemoradiation and adjuvant chemotherapy or only with adjuvant chemotherapy. TTF will be delivered through an external device on the scalp which apply electric field through the brain
Principal Investigator PI Sub PI's	Principal Investigator - Mr Isaac Phang, Neurosurgery Sub Investigator- Dr Erica Beaumont, clinical oncology Sub Investigator - Dr Tai-Chung Lam, clinical oncology
Research Nurse Team	Sonia Raj Senior Research Nurse, Terrie-Louise Cromie Research Practitioner, Allan Brown Research Nurse, Helen Cross Research Nurse
Drug therapy	No experimental drug therapy TTF is an FDA approved device which is applied through pieces of transducer array on the scalp. The array was connected to an external battery for electric field delivery
In the event that a patient calls this hotline for advise	TTF was well tolerated in most patients. The most common side effect is the scalp irritation which may cause itchiness, redness, pain or discharge. This should be readily treatable with hydrocortisone cream or topical antibiotics. Previous studies showed that TTF patients were not at higher risk of seizure. TTF Contact Sue Brabbon Mob 07442 895390